Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-15T18:22:14.170Z Has data issue: false hasContentIssue false
  • English
  • Français

P0106 - A comparision of switching strategies from risperidone to aripiprazole in patients with schizophrenia with insufficient efficacy/tolerability on risperidone (cn138-169)

Published online by Cambridge University Press:  16 April 2020

V. Rykmans ,
J.P. Kahn ,
A. Dillenschneider ,
L. Hanssens ,
S. Model ,
W. Kerselaers ,
J.Y. Loze  and
R. Sanchez
V. Rykmans
Affiliation:
Cabinet de Consultations, Brussels, Belgium
J.P. Kahn
Affiliation:
CHU de Nancy-Hôpital Jeanne D'Arc, Service Psychiatrie Et Psychologie Clinique, Dommartin Les Toul, France
A. Dillenschneider
Affiliation:
Bristol-Myers Squibb Company, Rueil-Malmaison Cedex, France
L. Hanssens
Affiliation:
Bristol-Myers Squibb Company, Braine L'Alleud, Belgium
S. Model
Affiliation:
Bristol-Myers Squibb Company, Munich, Germany
W. Kerselaers
Affiliation:
Bristol-Myers Squibb Company, Braine L'Alleud, Belgium
J.Y. Loze
Affiliation:
Otsuka Pharmaceutical France SAS, Rueil-Malmaison Cedex, France
R. Sanchez
Affiliation:
Bristol-Myers Squibb Company, Rueil-Malmaison Cedex, France

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background and Aim:

To evaluate safety, tolerability and overall effectiveness of a titrated- versus fixed-dose switching strategy from risperidone to aripiprazole in a general practice setting.

Methods:

This 12-week, multicentre, open-label study included patients with schizophrenia (DSM-IV-TR) experiencing insufficient efficacy and/or safety/tolerability issues while receiving risperidone for ≥6 weeks. Patients were randomized to titrated- or fixed-dose switching regimens.

Results:

Discontinuations due to AEs were similar between titrated- and fixed-dose strategies (3.5% vs. 5.0%; p=0.448). Titrated- and fixed-dose groups showed improvements (Week 12) in mean PANSS Total scores (–14.8 vs. –17.2; LOCF), mean CGI-I scores (2.9 vs. 2.8; p=0.425; LOCF), ASEX scores (–1.5 vs. –1.9 from baseline; OC), serum prolactin levels (−48.7 vs. −48.5 from baseline; OC) and SWN scores (+8.6 vs. +10.3 from baseline; p=0.223; OC). POM scores indicated a preference for aripiprazole compared with risperidone using either regimen. Both strategies showed improvements (titrated-dose vs. fixed-dose; Week 12; LOCF) in social cognition as indicated by decreased GEOPTE patient (–5.3 vs. –6.1), caregiver (–5.4 vs. –9.9) and index scores (–5.1 vs. –9.8).

Conclusion:

Switching to aripiprazole from risperidone can be effectively and safely achieved in a general practice setting through a slow down-titration of risperidone and either a titrated- or fixed-dose switching strategy for aripiprazole.

Type
Poster Session I: Schizophrenia and Psychosis
Information
European Psychiatry , Volume 23 , Issue S2: 16th AEP Congress - Abstract book - 16th AEP Congress , April 2008 , pp. S111
Copyright
Copyright © European Psychiatric Association 2008
Submit a response

Comments

No Comments have been published for this article.